Drugs / PGV001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05010200 | Jan 2022 → Jan 2027 expected | prostate cancer | Ashutosh Kumar Tewari | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03359239 | May 2019 → Oct 2021 | urothelial carcinoma | Matthew Galsky | Completed | Met primary |
| Phase 1 | NCT02721043 | Apr 2016 → Nov 2019 | cancer | Nina Bhardwaj | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PGV001 | “PGV001 is a peptide vaccine that is based on a patient's own tumor sequence.” NCT02721043 ↗ |
| Known as | Personalized Genomic Vaccine 001 | “The purpose of this study is to test the safety, tolerability, and immunogenicity of Personalized Genomic Vaccine 001 (PGV001) in subjects with advanced non-hematologic malignancies.” NCT02721043 ↗ |
| Modality | Vaccine | “PGV001 is a peptide vaccine” NCT02721043 ↗ |